我国实现全球首例再生胰岛移植

Core Viewpoint - A research team from China has successfully achieved the reconstruction of islet function and autonomous blood glucose regulation in type 1 diabetes patients through minimally invasive transplantation of regenerated islets (E-islet) derived from both autologous and allogeneic stem cells, marking a significant advancement in diabetes treatment [1][2][3]. Group 1: Research Background and Significance - Diabetes, particularly type 1 diabetes, poses a serious health threat in China, primarily affecting children and adolescents due to autoimmune disorders that destroy pancreatic beta cells, leading to insulin deficiency and uncontrolled blood glucose levels [1]. - Traditional islet transplantation is limited by a severe shortage of donors, making it inaccessible to many patients, thus highlighting the urgent need for scalable islet regeneration solutions in the medical community [1]. Group 2: Technological Advancements - The research team has developed a novel technology based on endodermal stem cells over more than two decades, successfully creating regenerated islets (E-islet) that can stabilize blood glucose levels when infused into patients [2]. Group 3: Clinical Research Findings - Clinical studies involving three patients demonstrated that both autologous and allogeneic E-islet transplantation can restore islet function, achieve blood glucose regulation, and reduce dependence on external insulin, thereby improving long-term blood glucose levels and decreasing the incidence of complications [3]. - The therapy currently requires long-term immunosuppressive treatment to prevent autoimmune relapse in type 1 diabetes, but future plans include gene editing to modify regenerated islets to evade immune system recognition, aiming for a complete cure for diabetes [3].